➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Last Updated: August 5, 2020

DrugPatentWatch Database Preview

GLUCAGON Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Glucagon patents expire, and when can generic versions of Glucagon launch?

Glucagon is a drug marketed by Lilly and Fresenius Kabi Usa and is included in three NDAs.

The generic ingredient in GLUCAGON is glucagon. There are twelve drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the glucagon profile page.

US ANDA Litigation and Generic Entry Outlook for Glucagon

A generic version of GLUCAGON was approved as glucagon by LILLY on September 11th, 1998.

  Start Trial

Drug patent expirations by year for GLUCAGON
Drug Prices for GLUCAGON

See drug prices for GLUCAGON

Recent Clinical Trials for GLUCAGON

Identify potential brand extensions & 505(b)(2) entrants

Translational Research Institute for Metabolism and Diabetes, FloridaPhase 2
Adrian VellaPhase 3
Steno Diabetes Center CopenhagenPhase 2

See all GLUCAGON clinical trials

Medical Subject Heading (MeSH) Categories for GLUCAGON

US Patents and Regulatory Information for GLUCAGON

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly GLUCAGON glucagon hydrochloride INJECTABLE;INJECTION 012122-001 Approved Prior to Jan 1, 1982 DISCN Yes No   Start Trial   Start Trial   Start Trial
Fresenius Kabi Usa GLUCAGON glucagon hydrochloride POWDER;INTRAMUSCULAR, INTRAVENOUS 201849-001 May 8, 2015 RX Yes Yes   Start Trial   Start Trial   Start Trial
Lilly GLUCAGON glucagon INJECTABLE;INJECTION 020928-001 Sep 11, 1998 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.